{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T12:03:50Z","timestamp":1793016230356,"version":"4.5.0"},"reference-count":88,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,7,4]],"date-time":"2023-07-04T00:00:00Z","timestamp":1688428800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,4]],"date-time":"2023-07-04T00:00:00Z","timestamp":1688428800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Heart Fail Rep"],"published-print":{"date-parts":[[2023,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose of the Review<\/jats:title>\n                <jats:p>Non-alcoholic fatty liver disease (NAFLD) and heart failure (HF) are two chronic diseases that have become important global public health problems. This narrative review provides a comprehensive overview of the association between NAFLD and increased risk of new-onset HF, briefly discusses the putative biological mechanisms linking these two conditions, and summarizes targeted pharmacotherapies for NAFLD that might also beneficially affect cardiac complications leading to new-onset HF.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Recent Findings<\/jats:title>\n                <jats:p>Recent observational cohort studies supported a significant association between NAFLD and the long-term risk of new-onset HF. Notably, this risk remained statistically significant even after adjustment for age, sex, ethnicity, adiposity measures, pre-existing type 2 diabetes and other common cardiometabolic risk factors. In addition, the risk of incident HF was further increased with more advanced liver disease, especially with higher severity of liver fibrosis. There are multiple potential pathophysiological mechanisms by which NAFLD (especially in its more advanced forms) may increase the risk of new-onset HF.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Summary<\/jats:title>\n                <jats:p>Because of the strong link existing between NAFLD and HF, more careful surveillance of these patients will be needed. However, further prospective and mechanistic studies are required to better decipher the existing but complex link between NAFLD and risk of new-onset HF.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s11897-023-00613-1","type":"journal-article","created":{"date-parts":[[2023,7,4]],"date-time":"2023-07-04T04:02:06Z","timestamp":1688443326000},"page":"308-319","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Non-Alcoholic Fatty Liver Disease as an Emerging Risk Factor for Heart Failure"],"prefix":"10.1007","volume":"20","author":[{"given":"Riccardo M.","family":"Inciardi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Mantovani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4325-3900","authenticated-orcid":false,"given":"Giovanni","family":"Targher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,4]]},"reference":[{"issue":"36","key":"613_CR1","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"42","author":"TA McDonagh","year":"2021","unstructured":"McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Bohm M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599\u2013726. https:\/\/doi.org\/10.1093\/eurheartj\/ehab368.","journal-title":"Eur Heart J"},{"issue":"4","key":"613_CR2","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","volume":"77","author":"ZM Younossi","year":"2023","unstructured":"Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, Henry L. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology. 2023;77(4):1335\u201347. https:\/\/doi.org\/10.1097\/HEP.0000000000000004.","journal-title":"Hepatology"},{"key":"613_CR3","doi-asserted-by":"publisher","first-page":"154170","DOI":"10.1016\/j.metabol.2020.154170","volume":"111S","author":"A Mantovani","year":"2020","unstructured":"Mantovani A, Scorletti E, Mosca A, Alisi A, Byrne CD, Targher G. Complications, morbidity and mortality of nonalcoholic fatty liver disease. Metabolism. 2020;111S:154170. https:\/\/doi.org\/10.1016\/j.metabol.2020.154170.","journal-title":"Metabolism"},{"issue":"10319","key":"613_CR4","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/S0140-6736(21)01701-3","volume":"399","author":"TH Karlsen","year":"2022","unstructured":"Karlsen TH, Sheron N, Zelber-Sagi S, Carrieri P, Dusheiko G, Bugianesi E, et al. The EASL-lancet liver commission: protecting the next generation of Europeans against liver disease complications and premature mortality. Lancet. 2022;399(10319):61\u2013116. https:\/\/doi.org\/10.1016\/S0140-6736(21)01701-3.","journal-title":"Lancet"},{"key":"613_CR5","doi-asserted-by":"publisher","unstructured":"AISF, SID, SIO. Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO). Nutr Metab Cardiovasc Dis. 2022;32(1):1\u201316. https:\/\/doi.org\/10.1016\/j.numecd.2021.04.028","DOI":"10.1016\/j.numecd.2021.04.028"},{"issue":"11","key":"613_CR6","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1016\/S2468-1253(21)00308-3","volume":"6","author":"A Mantovani","year":"2021","unstructured":"Mantovani A, Csermely A, Petracca G, Beatrice G, Corey KE, Simon TG, et al. Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2021;6(11):903\u201313. https:\/\/doi.org\/10.1016\/S2468-1253(21)00308-3.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"6","key":"613_CR7","doi-asserted-by":"publisher","first-page":"e168","DOI":"10.1161\/ATV.0000000000000153","volume":"42","author":"PB Duell","year":"2022","unstructured":"Duell PB, Welty FK, Miller M, Chait A, Hammond G, Ahmad Z, et al. Nonalcoholic fatty liver disease and cardiovascular risk: a scientific statement from the American heart association. Arterioscler Thromb Vasc Biol. 2022;42(6):e168\u201385. https:\/\/doi.org\/10.1161\/ATV.0000000000000153.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"7","key":"613_CR8","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1038\/s41575-018-0010-0","volume":"15","author":"QM Anstee","year":"2018","unstructured":"Anstee QM, Mantovani A, Tilg H, Targher G. Risk of cardiomyopathy and cardiac arrhythmias in patients with nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol. 2018;15(7):425\u201339. https:\/\/doi.org\/10.1038\/s41575-018-0010-0.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"613_CR9","doi-asserted-by":"publisher","unstructured":"\u2022 Mantovani A, Byrne CD, Benfari G, Bonapace S, Simon TG, Targher G. Risk of heart failure in patients with nonalcoholic fatty liver disease: JACC review topic of the week. J Am Coll Cardiol. 2022;79(2):180\u201391. https:\/\/doi.org\/10.1016\/j.jacc.2021.11.007. This review provides an overview of the association between NAFLD and increased risk of HF, discuss the underlying pathophysiological mechanisms that link these diseases, and summarize targeted pharmacological treatments for NAFLD that might also reduce the risk of HF.","DOI":"10.1016\/j.jacc.2021.11.007"},{"issue":"6","key":"613_CR10","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1093\/eurjpc\/zwab212","volume":"29","author":"L Alon","year":"2022","unstructured":"Alon L, Corica B, Raparelli V, Cangemi R, Basili S, Proietti M, et al. Risk of cardiovascular events in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis. Eur J Prev Cardiol. 2022;29(6):938\u201346. https:\/\/doi.org\/10.1093\/eurjpc\/zwab212.","journal-title":"Eur J Prev Cardiol"},{"issue":"6","key":"613_CR11","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1111\/apt.17158","volume":"56","author":"L Henry","year":"2022","unstructured":"Henry L, Paik J, Younossi ZM. Review article: the epidemiologic burden of non-alcoholic fatty liver disease across the world. Aliment Pharmacol Ther. 2022;56(6):942\u201356. https:\/\/doi.org\/10.1111\/apt.17158.","journal-title":"Aliment Pharmacol Ther"},{"key":"613_CR12","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000323","author":"ME Rinella","year":"2023","unstructured":"Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, Abdelmalek MF, Caldwell S, Barb D, et al. AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023. https:\/\/doi.org\/10.1097\/HEP.0000000000000323.","journal-title":"Hepatology"},{"issue":"4","key":"613_CR13","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/j.jhep.2019.06.021","volume":"71","author":"ZM Younossi","year":"2019","unstructured":"Younossi ZM, Golabi P, de Avila L, Paik JM, Srishord M, Fukui N, et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis. J Hepatol. 2019;71(4):793\u2013801. https:\/\/doi.org\/10.1016\/j.jhep.2019.06.021.","journal-title":"J Hepatol"},{"issue":"1","key":"613_CR14","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/S2468-1253(22)00317-X","volume":"8","author":"J Quek","year":"2023","unstructured":"Quek J, Chan KE, Wong ZY, Tan C, Tan B, Lim WH, et al. Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2023;8(1):20\u201330. https:\/\/doi.org\/10.1016\/S2468-1253(22)00317-X.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"4","key":"613_CR15","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1002\/hep.30626","volume":"70","author":"A Lonardo","year":"2019","unstructured":"Lonardo A, Nascimbeni F, Ballestri S, Fairweather D, Win S, Than TA, et al. Sex differences in nonalcoholic fatty liver disease: state of the art and identification of research gaps. Hepatology. 2019;70(4):1457\u201369. https:\/\/doi.org\/10.1002\/hep.30626.","journal-title":"Hepatology"},{"issue":"3","key":"613_CR16","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1111\/apt.15830","volume":"52","author":"ZM Younossi","year":"2020","unstructured":"Younossi ZM, Corey KE, Alkhouri N, Noureddin M, Jacobson I, Lam B, et al. Clinical assessment for high-risk patients with non-alcoholic fatty liver disease in primary care and diabetology practices. Aliment Pharmacol Ther. 2020;52(3):513\u201326. https:\/\/doi.org\/10.1111\/apt.15830.","journal-title":"Aliment Pharmacol Ther"},{"issue":"9","key":"613_CR17","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/S2468-1253(22)00165-0","volume":"7","author":"K Riazi","year":"2022","unstructured":"Riazi K, Azhari H, Charette JH, Underwood FE, King JA, Afshar EE, et al. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2022;7(9):851\u201361. https:\/\/doi.org\/10.1016\/S2468-1253(22)00165-0.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"613_CR18","doi-asserted-by":"publisher","unstructured":"\u2022 European Association for the Study of the L, European Association for the Study of D, European Association for the Study of O. EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64(6):1388\u2013402. https:\/\/doi.org\/10.1016\/j.jhep.2015.11.004. European guidelines regarding the diagnosis and management of NAFLD and its advanced forms.","DOI":"10.1016\/j.jhep.2015.11.004"},{"issue":"6","key":"613_CR19","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1002\/hep.20701","volume":"41","author":"DE Kleiner","year":"2005","unstructured":"Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41(6):1313\u201321. https:\/\/doi.org\/10.1002\/hep.20701.","journal-title":"Hepatology"},{"issue":"1","key":"613_CR20","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","volume":"73","author":"M Eslam","year":"2020","unstructured":"Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-Gomez M, et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J Hepatol. 2020;73(1):202\u20139. https:\/\/doi.org\/10.1016\/j.jhep.2020.03.039.","journal-title":"J Hepatol"},{"key":"613_CR21","doi-asserted-by":"publisher","unstructured":"Eslam M, Sanyal AJ, George J, International Consensus P. MAFLD: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology. 2020;158(7):1999\u20132014 e1. https:\/\/doi.org\/10.1053\/j.gastro.2019.11.312","DOI":"10.1053\/j.gastro.2019.11.312"},{"issue":"2","key":"613_CR22","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1111\/liv.15139","volume":"42","author":"I Ayada","year":"2022","unstructured":"Ayada I, van Kleef LA, Alferink LJM, Li P, de Knegt RJ, Pan Q. Systematically comparing epidemiological and clinical features of MAFLD and NAFLD by meta-analysis: focusing on the non-overlap groups. Liver Int. 2022;42(2):277\u201387. https:\/\/doi.org\/10.1111\/liv.15139.","journal-title":"Liver Int"},{"key":"613_CR23","doi-asserted-by":"publisher","first-page":"k2734","DOI":"10.1136\/bmj.k2734","volume":"362","author":"CD Byrne","year":"2018","unstructured":"Byrne CD, Patel J, Scorletti E, Targher G. Tests for diagnosing and monitoring non-alcoholic fatty liver disease in adults. BMJ. 2018;362:k2734. https:\/\/doi.org\/10.1136\/bmj.k2734.","journal-title":"BMJ."},{"issue":"8","key":"613_CR24","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1038\/s41575-018-0014-9","volume":"15","author":"VW Wong","year":"2018","unstructured":"Wong VW, Adams LA, de Ledinghen V, Wong GL, Sookoian S. Noninvasive biomarkers in NAFLD and NASH - current progress and future promise. Nat Rev Gastroenterol Hepatol. 2018;15(8):461\u201378. https:\/\/doi.org\/10.1038\/s41575-018-0014-9.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"3","key":"613_CR25","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1002\/hep.24452","volume":"54","author":"R Hernaez","year":"2011","unstructured":"Hernaez R, Lazo M, Bonekamp S, Kamel I, Brancati FL, Guallar E, et al. Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: a meta-analysis. Hepatology. 2011;54(3):1082\u201390. https:\/\/doi.org\/10.1002\/hep.24452.","journal-title":"Hepatology."},{"issue":"5","key":"613_CR26","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1053\/j.gastro.2018.12.036","volume":"156","author":"L Castera","year":"2019","unstructured":"Castera L, Friedrich-Rust M, Loomba R. Noninvasive assessment of liver disease in patients with nonalcoholic fatty liver disease. Gastroenterology. 2019;156(5):1264-81.e4. https:\/\/doi.org\/10.1053\/j.gastro.2018.12.036.","journal-title":"Gastroenterology."},{"issue":"4","key":"613_CR27","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1016\/j.jhep.2021.04.044","volume":"75","author":"EA Selvaraj","year":"2021","unstructured":"Selvaraj EA, Mozes FE, Jayaswal ANA, Zafarmand MH, Vali Y, Lee JA, et al. Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: a systematic review and meta-analysis. J Hepatol. 2021;75(4):770\u201385. https:\/\/doi.org\/10.1016\/j.jhep.2021.04.044.","journal-title":"J Hepatol"},{"issue":"9","key":"613_CR28","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1161\/ATVBAHA.110.207340","volume":"30","author":"R Dhingra","year":"2010","unstructured":"Dhingra R, Gona P, Wang TJ, Fox CS, D\u2019Agostino RB Sr, Vasan RS. Serum gamma-glutamyl transferase and risk of heart failure in the community. Arterioscler Thromb Vasc Biol. 2010;30(9):1855\u201360. https:\/\/doi.org\/10.1161\/ATVBAHA.110.207340.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"3","key":"613_CR29","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1161\/ATVBAHA.111.240457","volume":"32","author":"SG Wannamethee","year":"2012","unstructured":"Wannamethee SG, Whincup PH, Shaper AG, Lennon L, Sattar N. Gamma-glutamyltransferase, hepatic enzymes, and risk of incident heart failure in older men. Arterioscler Thromb Vasc Biol. 2012;32(3):830\u20135. https:\/\/doi.org\/10.1161\/ATVBAHA.111.240457.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"3","key":"613_CR30","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1136\/heartjnl-2012-302972","volume":"99","author":"Y Wang","year":"2013","unstructured":"Wang Y, Tuomilehto J, Jousilahti P, Salomaa V, Li B, Antikainen R, et al. Serum gamma-glutamyltransferase and the risk of heart failure in men and women in Finland. Heart. 2013;99(3):163\u20137. https:\/\/doi.org\/10.1136\/heartjnl-2012-302972.","journal-title":"Heart"},{"issue":"10","key":"613_CR31","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1016\/j.cgh.2020.12.022","volume":"19","author":"H Lee","year":"2021","unstructured":"Lee H, Lee YH, Kim SU, Kim HC. Metabolic dysfunction-associated fatty liver disease and incident cardiovascular disease risk: a nationwide cohort study. Clin Gastroenterol Hepatol. 2021;19(10):2138-47.e10. https:\/\/doi.org\/10.1016\/j.cgh.2020.12.022.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"9","key":"613_CR32","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1136\/gutjnl-2021-325724","volume":"71","author":"TG Simon","year":"2022","unstructured":"Simon TG, Roelstraete B, Hagstrom H, Sundstrom J, Ludvigsson JF. Non-alcoholic fatty liver disease and incident major adverse cardiovascular events: results from a nationwide histology cohort. Gut. 2022;71(9):1867\u201375. https:\/\/doi.org\/10.1136\/gutjnl-2021-325724.","journal-title":"Gut"},{"key":"613_CR33","doi-asserted-by":"publisher","unstructured":"\u2022 Mantovani A, Petracca G, Csermely A, Beatrice G, Bonapace S, Rossi A, et al. Non-alcoholic fatty liver disease and risk of new-onset heart failure: an updated meta-analysis of about 11 million individuals. Gut. 2022. https:\/\/doi.org\/10.1136\/gutjnl-2022-327672. Updated systematic review and meta-analysis showing that NAFLD is associated with a 1.5-fold higher long-term risk of new-onset HF, independent of the presence of diabetes, hypertension and other common cardiometabolic risk factors.","DOI":"10.1136\/gutjnl-2022-327672"},{"issue":"3","key":"613_CR34","doi-asserted-by":"publisher","first-page":"453","DOI":"10.14309\/ajg.0000000000001606","volume":"117","author":"J Vieira Barbosa","year":"2022","unstructured":"Vieira Barbosa J, Milligan S, Frick A, Broestl J, Younossi Z, Afdhal N, et al. Fibrosis-4 index can independently predict major adverse cardiovascular events in nonalcoholic fatty liver disease. Am J Gastroenterol. 2022;117(3):453\u201361. https:\/\/doi.org\/10.14309\/ajg.0000000000001606.","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"613_CR35","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1002\/ehf2.13250","volume":"8","author":"AE Peters","year":"2021","unstructured":"Peters AE, Pandey A, Ayers C, Wegermann K, McGarrah RW, Grodin JL, et al. Association of liver fibrosis risk scores with clinical outcomes in patients with heart failure with preserved ejection fraction: findings from TOPCAT. ESC Heart Fail. 2021;8(2):842\u20138. https:\/\/doi.org\/10.1002\/ehf2.13250.","journal-title":"ESC Heart Fail"},{"issue":"2","key":"613_CR36","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1002\/ehf2.12222","volume":"5","author":"A Yoshihisa","year":"2018","unstructured":"Yoshihisa A, Sato Y, Yokokawa T, Sato T, Suzuki S, Oikawa M, et al. Liver fibrosis score predicts mortality in heart failure patients with preserved ejection fraction. ESC Heart Fail. 2018;5(2):262\u201370. https:\/\/doi.org\/10.1002\/ehf2.12222.","journal-title":"ESC Heart Fail"},{"issue":"3","key":"613_CR37","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1136\/gutjnl-2022-328105","volume":"72","author":"TG Simon","year":"2023","unstructured":"Simon TG, Roelstraete B, Alkhouri N, Hagstrom H, Sundstrom J, Ludvigsson JF. Cardiovascular disease risk in paediatric and young adult non-alcoholic fatty liver disease. Gut. 2023;72(3):573\u201380. https:\/\/doi.org\/10.1136\/gutjnl-2022-328105.","journal-title":"Gut"},{"issue":"22","key":"613_CR38","doi-asserted-by":"publisher","first-page":"e021654","DOI":"10.1161\/JAHA.121.021654","volume":"10","author":"M Fudim","year":"2021","unstructured":"Fudim M, Zhong L, Patel KV, Khera R, Abdelmalek MF, Diehl AM, et al. Nonalcoholic fatty liver disease and risk of heart failure among medicare beneficiaries. J Am Heart Assoc. 2021;10(22):e021654. https:\/\/doi.org\/10.1161\/JAHA.121.021654.","journal-title":"J Am Heart Assoc."},{"issue":"3","key":"613_CR39","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1002\/hep.27869","volume":"62","author":"LB VanWagner","year":"2015","unstructured":"VanWagner LB, Wilcox JE, Colangelo LA, Lloyd-Jones DM, Carr JJ, Lima JA, et al. Association of nonalcoholic fatty liver disease with subclinical myocardial remodeling and dysfunction: a population-based study. Hepatology. 2015;62(3):773\u201383. https:\/\/doi.org\/10.1002\/hep.27869.","journal-title":"Hepatology"},{"issue":"8","key":"613_CR40","doi-asserted-by":"publisher","first-page":"e0135329","DOI":"10.1371\/journal.pone.0135329","volume":"10","author":"A Mantovani","year":"2015","unstructured":"Mantovani A, Pernigo M, Bergamini C, Bonapace S, Lipari P, Pichiri I, et al. Nonalcoholic fatty liver disease is independently associated with early left ventricular diastolic dysfunction in patients with type 2 diabetes. PLoS One. 2015;10(8):e0135329. https:\/\/doi.org\/10.1371\/journal.pone.0135329.","journal-title":"PLoS One"},{"issue":"7","key":"613_CR41","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/S2468-1253(21)00020-0","volume":"6","author":"G Targher","year":"2021","unstructured":"Targher G, Tilg H, Byrne CD. Non-alcoholic fatty liver disease: a multisystem disease requiring a multidisciplinary and holistic approach. Lancet Gastroenterol Hepatol. 2021;6(7):578\u201388. https:\/\/doi.org\/10.1016\/S2468-1253(21)00020-0.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"1","key":"613_CR42","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1038\/nrgastro.2016.147","volume":"14","author":"H Tilg","year":"2017","unstructured":"Tilg H, Moschen AR, Roden M. NAFLD and diabetes mellitus. Nat Rev Gastroenterol Hepatol. 2017;14(1):32\u201342. https:\/\/doi.org\/10.1038\/nrgastro.2016.147.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"6","key":"613_CR43","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1161\/01.cir.96.6.1937","volume":"96","author":"R Kacimi","year":"1997","unstructured":"Kacimi R, Long CS, Karliner JS. Chronic hypoxia modulates the interleukin-1beta-stimulated inducible nitric oxide synthase pathway in cardiac myocytes. Circulation. 1997;96(6):1937\u201343. https:\/\/doi.org\/10.1161\/01.cir.96.6.1937.","journal-title":"Circulation"},{"key":"613_CR44","doi-asserted-by":"publisher","first-page":"695047","DOI":"10.3389\/fphys.2021.695047","volume":"12","author":"H Li","year":"2021","unstructured":"Li H, Chen C, Wang DW. Inflammatory cytokines, immune cells, and organ interactions in heart failure. Front Physiol. 2021;12:695047. https:\/\/doi.org\/10.3389\/fphys.2021.695047.","journal-title":"Front Physiol."},{"issue":"5","key":"613_CR45","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1016\/s0735-1097(00)00526-x","volume":"35","author":"T Tatsumi","year":"2000","unstructured":"Tatsumi T, Matoba S, Kawahara A, Keira N, Shiraishi J, Akashi K, et al. Cytokine-induced nitric oxide production inhibits mitochondrial energy production and impairs contractile function in rat cardiac myocytes. J Am Coll Cardiol. 2000;35(5):1338\u201346. https:\/\/doi.org\/10.1016\/s0735-1097(00)00526-x.","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"613_CR46","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1016\/s0735-1097(96)00268-9","volume":"28","author":"M Testa","year":"1996","unstructured":"Testa M, Yeh M, Lee P, Fanelli R, Loperfido F, Berman JW, et al. Circulating levels of cytokines and their endogenous modulators in patients with mild to severe congestive heart failure due to coronary artery disease or hypertension. J Am Coll Cardiol. 1996;28(4):964\u201371. https:\/\/doi.org\/10.1016\/s0735-1097(96)00268-9.","journal-title":"J Am Coll Cardiol"},{"issue":"22","key":"613_CR47","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1093\/eurheartj\/ehy128","volume":"39","author":"LF Buckley","year":"2018","unstructured":"Buckley LF, Abbate A. Interleukin-1 blockade in cardiovascular diseases: a clinical update. Eur Heart J. 2018;39(22):2063\u20139. https:\/\/doi.org\/10.1093\/eurheartj\/ehy128.","journal-title":"Eur Heart J"},{"key":"613_CR48","doi-asserted-by":"publisher","unstructured":"Malesza IJ, Malesza M, Walkowiak J, Mussin N, Walkowiak D, Aringazina R, et al. High-fat, western-style diet, systemic inflammation, and gut microbiota: a narrative review. Cells. 2021;10(11). https:\/\/doi.org\/10.3390\/cells10113164","DOI":"10.3390\/cells10113164"},{"key":"613_CR49","doi-asserted-by":"publisher","unstructured":"Beam A, Clinger E, Hao L. Effect of diet and dietary components on the composition of the gut microbiota. Nutrients. 2021;13(8). https:\/\/doi.org\/10.3390\/nu13082795","DOI":"10.3390\/nu13082795"},{"key":"613_CR50","doi-asserted-by":"publisher","unstructured":"Do MH, Lee E, Oh MJ, Kim Y, Park HY. High-glucose or -fructose diet cause changes of the gut microbiota and metabolic disorders in mice without body weight change. Nutrients. 2018;10(6). https:\/\/doi.org\/10.3390\/nu10060761","DOI":"10.3390\/nu10060761"},{"issue":"2","key":"613_CR51","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1136\/gutjnl-2018-316307","volume":"68","author":"H Chu","year":"2019","unstructured":"Chu H, Duan Y, Yang L, Schnabl B. Small metabolites, possible big changes: a microbiota-centered view of non-alcoholic fatty liver disease. Gut. 2019;68(2):359\u201370. https:\/\/doi.org\/10.1136\/gutjnl-2018-316307.","journal-title":"Gut"},{"issue":"2","key":"613_CR52","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.cmet.2023.01.006","volume":"35","author":"N Stefan","year":"2023","unstructured":"Stefan N, Schick F, Birkenfeld AL, Haring HU, White MF. The role of hepatokines in NAFLD. Cell Metab. 2023;35(2):236\u201352. https:\/\/doi.org\/10.1016\/j.cmet.2023.01.006.","journal-title":"Cell Metab"},{"issue":"9","key":"613_CR53","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1038\/nrendo.2017.56","volume":"13","author":"RCR Meex","year":"2017","unstructured":"Meex RCR, Watt MJ. Hepatokines: linking nonalcoholic fatty liver disease and insulin resistance. Nat Rev Endocrinol. 2017;13(9):509\u201320. https:\/\/doi.org\/10.1038\/nrendo.2017.56.","journal-title":"Nat Rev Endocrinol"},{"issue":"3","key":"613_CR54","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.ijcard.2013.08.077","volume":"169","author":"S Lim","year":"2013","unstructured":"Lim S, Meigs JB. Ectopic fat and cardiometabolic and vascular risk. Int J Cardiol. 2013;169(3):166\u201376. https:\/\/doi.org\/10.1016\/j.ijcard.2013.08.077.","journal-title":"Int J Cardiol"},{"issue":"4","key":"613_CR55","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1016\/j.jhep.2014.11.030","volume":"62","author":"S Petta","year":"2015","unstructured":"Petta S, Argano C, Colomba D, Camma C, Di Marco V, Cabibi D, et al. Epicardial fat, cardiac geometry and cardiac function in patients with non-alcoholic fatty liver disease: association with the severity of liver disease. J Hepatol. 2015;62(4):928\u201333. https:\/\/doi.org\/10.1016\/j.jhep.2014.11.030.","journal-title":"J Hepatol"},{"issue":"8","key":"613_CR56","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1002\/ejhf.2577","volume":"24","author":"RM Inciardi","year":"2022","unstructured":"Inciardi RM, Chandra A. Epicardial adipose tissue in heart failure: risk factor or mediator? Eur J Heart Fail. 2022;24(8):1357\u20138. https:\/\/doi.org\/10.1002\/ejhf.2577.","journal-title":"Eur J Heart Fail"},{"issue":"2","key":"613_CR57","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.jhep.2017.09.003","volume":"68","author":"M Eslam","year":"2018","unstructured":"Eslam M, Valenti L, Romeo S. Genetics and epigenetics of NAFLD and NASH: clinical impact. J Hepatol. 2018;68(2):268\u201379. https:\/\/doi.org\/10.1016\/j.jhep.2017.09.003.","journal-title":"J Hepatol"},{"issue":"4","key":"613_CR58","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.jhep.2017.05.016","volume":"67","author":"M Romero-Gomez","year":"2017","unstructured":"Romero-Gomez M, Zelber-Sagi S, Trenell M. Treatment of NAFLD with diet, physical activity and exercise. J Hepatol. 2017;67(4):829\u201346. https:\/\/doi.org\/10.1016\/j.jhep.2017.05.016.","journal-title":"J Hepatol"},{"issue":"3","key":"613_CR59","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1038\/nrgastro.2016.170","volume":"14","author":"NT Nguyen","year":"2017","unstructured":"Nguyen NT, Varela JE. Bariatric surgery for obesity and metabolic disorders: state of the art. Nat Rev Gastroenterol Hepatol. 2017;14(3):160\u20139. https:\/\/doi.org\/10.1038\/nrgastro.2016.170.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"6","key":"613_CR60","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1016\/j.cgh.2018.10.017","volume":"17","author":"Y Lee","year":"2019","unstructured":"Lee Y, Doumouras AG, Yu J, Brar K, Banfield L, Gmora S, et al. Complete resolution of nonalcoholic fatty liver disease after bariatric surgery: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2019;17(6):1040-60.e11. https:\/\/doi.org\/10.1016\/j.cgh.2018.10.017.","journal-title":"Clin Gastroenterol Hepatol."},{"issue":"10390","key":"613_CR61","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1016\/S0140-6736(23)00634-7","volume":"401","author":"O Verrastro","year":"2023","unstructured":"Verrastro O, Panunzi S, Castagneto-Gissey L, De Gaetano A, Lembo E, Capristo E, et al. Bariatric-metabolic surgery versus lifestyle intervention plus best medical care in non-alcoholic steatohepatitis (BRAVES): a multicentre, open-label, randomised trial. Lancet. 2023;401(10390):1786\u201397. https:\/\/doi.org\/10.1016\/S0140-6736(23)00634-7.","journal-title":"Lancet"},{"issue":"20","key":"613_CR62","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1001\/jama.2021.19569","volume":"326","author":"A Aminian","year":"2021","unstructured":"Aminian A, Al-Kurd A, Wilson R, Bena J, Fayazzadeh H, Singh T, et al. Association of bariatric surgery with major adverse liver and cardiovascular outcomes in patients with biopsy-proven nonalcoholic steatohepatitis. JAMA. 2021;326(20):2031\u201342. https:\/\/doi.org\/10.1001\/jama.2021.19569.","journal-title":"JAMA"},{"key":"613_CR63","doi-asserted-by":"publisher","unstructured":"Krishnan A, Hadi Y, Alqahtani SA, Woreta TA, Fang W, Abunnaja S, et al. Cardiovascular outcomes and mortality after bariatric surgery in patients with nonalcoholic fatty liver disease and obesity. JAMA Netw Open. 2023;6(4):e237188. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.7188","DOI":"10.1001\/jamanetworkopen.2023.7188"},{"issue":"4","key":"613_CR64","doi-asserted-by":"publisher","first-page":"4277","DOI":"10.1016\/j.ijcard.2013.04.202","volume":"168","author":"F Graziani","year":"2013","unstructured":"Graziani F, Leone AM, Cialdella P, Basile E, Pennestri F, Della Bona R, et al. Effects of bariatric surgery on cardiac remodeling: clinical and pathophysiologic implications. Int J Cardiol. 2013;168(4):4277\u20139. https:\/\/doi.org\/10.1016\/j.ijcard.2013.04.202.","journal-title":"Int J Cardiol"},{"issue":"1","key":"613_CR65","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.soard.2017.09.534","volume":"14","author":"TL Kindel","year":"2018","unstructured":"Kindel TL, Strande JL. Bariatric surgery as a treatment for heart failure: review of the literature and potential mechanisms. Surg Obes Relat Dis. 2018;14(1):117\u201322. https:\/\/doi.org\/10.1016\/j.soard.2017.09.534.","journal-title":"Surg Obes Relat Dis"},{"issue":"3","key":"613_CR66","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1007\/s10741-021-10078-w","volume":"27","author":"T Datta","year":"2022","unstructured":"Datta T, Lee AJ, Cain R, McCarey M, Whellan DJ. Weighing in on heart failure: the potential impact of bariatric surgery. Heart Fail Rev. 2022;27(3):755\u201366. https:\/\/doi.org\/10.1007\/s10741-021-10078-w.","journal-title":"Heart Fail Rev"},{"issue":"2","key":"613_CR67","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/S2468-1253(22)00338-7","volume":"8","author":"G Targher","year":"2023","unstructured":"Targher G, Mantovani A, Byrne CD. Mechanisms and possible hepatoprotective effects of glucagon-like peptide-1 receptor agonists and other incretin receptor agonists in non-alcoholic fatty liver disease. Lancet Gastroenterol Hepatol. 2023;8(2):179\u201391. https:\/\/doi.org\/10.1016\/S2468-1253(22)00338-7.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"613_CR68","doi-asserted-by":"publisher","unstructured":"Mantovani A, Petracca G, Beatrice G, Csermely A, Lonardo A, Targher G. Glucagon-Like Peptide-1 receptor agonists for treatment of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: an updated meta-analysis of randomized controlled trials. Metabolites. 2021;11(2). https:\/\/doi.org\/10.3390\/metabo11020073.","DOI":"10.3390\/metabo11020073."},{"key":"613_CR69","doi-asserted-by":"publisher","unstructured":"Mantovani A, Petracca G, Csermely A, Beatrice G, Targher G. Sodium-glucose cotransporter-2 inhibitors for treatment of nonalcoholic fatty liver disease: a meta-analysis of randomized controlled trials. Metabolites. 2020;11(1). https:\/\/doi.org\/10.3390\/metabo11010022.","DOI":"10.3390\/metabo11010022"},{"key":"613_CR70","doi-asserted-by":"publisher","unstructured":"\u2022 Mantovani A, Byrne CD, Targher G. Efficacy of peroxisome proliferator-activated receptor agonists, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors for treatment of non-alcoholic fatty liver disease: a systematic review. Lancet Gastroenterol Hepatol. 2022;7(4):367\u201378. https:\/\/doi.org\/10.1016\/S2468-1253(21)00261-2. Recent systematic review showing the efficacy and safety of peroxisome proliferator-activated receptor agonists, glucagon-like peptide-1 receptor agonists, and sodium-glucose cotransporter-2 inhibitors for the treatment of NAFLD.","DOI":"10.1016\/S2468-1253(21)00261-2"},{"issue":"10","key":"613_CR71","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/S2213-8587(19)30249-9","volume":"7","author":"SL Kristensen","year":"2019","unstructured":"Kristensen SL, Rorth R, Jhund PS, Docherty KF, Sattar N, Preiss D, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol. 2019;7(10):776\u201385. https:\/\/doi.org\/10.1016\/S2213-8587(19)30249-9.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"613_CR72","doi-asserted-by":"publisher","first-page":"m4573","DOI":"10.1136\/bmj.m4573","volume":"372","author":"SC Palmer","year":"2021","unstructured":"Palmer SC, Tendal B, Mustafa RA, Vandvik PO, Li S, Hao Q, et al. Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials. BMJ. 2021;372:m4573. https:\/\/doi.org\/10.1136\/bmj.m4573.","journal-title":"BMJ."},{"key":"613_CR73","doi-asserted-by":"publisher","unstructured":"\u2022 Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American association for the study of liver diseases. Hepatology. 2018;67(1):328\u201357. https:\/\/doi.org\/10.1002\/hep.29367. American guidelines regarding the diagnosis and management of NAFLD and its advanced forms.","DOI":"10.1002\/hep.29367"},{"issue":"4","key":"613_CR74","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.jacc.2019.11.031","volume":"75","author":"TA Zelniker","year":"2020","unstructured":"Zelniker TA, Braunwald E. Mechanisms of cardiorenal effects of sodium-glucose cotransporter 2 inhibitors: JACC state-of-the-art review. J Am Coll Cardiol. 2020;75(4):422\u201334. https:\/\/doi.org\/10.1016\/j.jacc.2019.11.031.","journal-title":"J Am Coll Cardiol"},{"issue":"21","key":"613_CR75","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1056\/NEJMra2115011","volume":"386","author":"E Braunwald","year":"2022","unstructured":"Braunwald E. Gliflozins in the management of cardiovascular disease. N Engl J Med. 2022;386(21):2024\u201334. https:\/\/doi.org\/10.1056\/NEJMra2115011.","journal-title":"N Engl J Med"},{"key":"613_CR76","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.ahj.2020.10.064","volume":"232","author":"HM Salah","year":"2021","unstructured":"Salah HM, Al\u2019Aref SJ, Khan MS, Al-Hawwas M, Vallurupalli S, Mehta JL, et al. Effect of sodium-glucose cotransporter 2 inhibitors on cardiovascular and kidney outcomes-Systematic review and meta-analysis of randomized placebo-controlled trials. Am Heart J. 2021;232:10\u201322. https:\/\/doi.org\/10.1016\/j.ahj.2020.10.064.","journal-title":"Am Heart J"},{"issue":"4","key":"613_CR77","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/S2213-8587(23)00009-8","volume":"11","author":"M Schechter","year":"2023","unstructured":"Schechter M, Wiviott SD, Raz I, Goodrich EL, Rozenberg A, Yanuv I, et al. Effects of dapagliflozin on hospitalisations in people with type 2 diabetes: post-hoc analyses of the DECLARE-TIMI 58 trial. Lancet Diabetes Endocrinol. 2023;11(4):233\u201341. https:\/\/doi.org\/10.1016\/S2213-8587(23)00009-8.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"10354","key":"613_CR78","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/S0140-6736(22)01429-5","volume":"400","author":"M Vaduganathan","year":"2022","unstructured":"Vaduganathan M, Docherty KF, Claggett BL, Jhund PS, de Boer RA, Hernandez AF, et al. SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials. Lancet. 2022;400(10354):757\u201367. https:\/\/doi.org\/10.1016\/S0140-6736(22)01429-5.","journal-title":"Lancet"},{"issue":"15","key":"613_CR79","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","volume":"383","author":"M Packer","year":"2020","unstructured":"Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383(15):1413\u201324. https:\/\/doi.org\/10.1056\/NEJMoa2022190.","journal-title":"N Engl J Med"},{"issue":"21","key":"613_CR80","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE, Kober L, Kosiborod MN, Martinez FA, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995\u20132008. https:\/\/doi.org\/10.1056\/NEJMoa1911303.","journal-title":"N Engl J Med"},{"issue":"23","key":"613_CR81","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1161\/CIRCULATIONAHA.121.058929","volume":"145","author":"M Vaduganathan","year":"2022","unstructured":"Vaduganathan M, Claggett BL, Inciardi RM, Fonarow GC, McMurray JJV, Solomon SD. Estimating the benefits of combination medical therapy in heart failure with mildly reduced and preserved ejection fraction. Circulation. 2022;145(23):1741\u20133. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.121.058929.","journal-title":"Circulation"},{"issue":"1","key":"613_CR82","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1053\/gast.2001.25480","volume":"121","author":"JR Jonsson","year":"2001","unstructured":"Jonsson JR, Clouston AD, Ando Y, Kelemen LI, Horn MJ, Adamson MD, et al. Angiotensin-converting enzyme inhibition attenuates the progression of rat hepatic fibrosis. Gastroenterology. 2001;121(1):148\u201355. https:\/\/doi.org\/10.1053\/gast.2001.25480.","journal-title":"Gastroenterology"},{"issue":"3","key":"613_CR83","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1002\/hep.23419","volume":"51","author":"M Moreno","year":"2010","unstructured":"Moreno M, Gonzalo T, Kok RJ, Sancho-Bru P, van Beuge M, Swart J, et al. Reduction of advanced liver fibrosis by short-term targeted delivery of an angiotensin receptor blocker to hepatic stellate cells in rats. Hepatology. 2010;51(3):942\u201352. https:\/\/doi.org\/10.1002\/hep.23419.","journal-title":"Hepatology"},{"issue":"6","key":"613_CR84","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1002\/hep.21638","volume":"45","author":"A Hirose","year":"2007","unstructured":"Hirose A, Ono M, Saibara T, Nozaki Y, Masuda K, Yoshioka A, et al. Angiotensin II type 1 receptor blocker inhibits fibrosis in rat nonalcoholic steatohepatitis. Hepatology. 2007;45(6):1375\u201381. https:\/\/doi.org\/10.1002\/hep.21638.","journal-title":"Hepatology"},{"issue":"1","key":"613_CR85","doi-asserted-by":"publisher","first-page":"4003","DOI":"10.1038\/s41598-019-40322-1","volume":"9","author":"JG Park","year":"2019","unstructured":"Park JG, Mok JS, Han YI, Park TS, Kang KW, Choi CS, et al. Connectivity mapping of angiotensin-PPAR interactions involved in the amelioration of non-alcoholic steatohepatitis by Telmisartan. Sci Rep. 2019;9(1):4003. https:\/\/doi.org\/10.1038\/s41598-019-40322-1.","journal-title":"Sci Rep"},{"issue":"5","key":"613_CR86","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1002\/hep.24558","volume":"54","author":"DM Torres","year":"2011","unstructured":"Torres DM, Jones FJ, Shaw JC, Williams CD, Ward JA, Harrison SA. Rosiglitazone versus rosiglitazone and metformin versus rosiglitazone and losartan in the treatment of nonalcoholic steatohepatitis in humans: a 12-month randomized, prospective, open- label trial. Hepatology. 2011;54(5):1631\u20139. https:\/\/doi.org\/10.1002\/hep.24558.","journal-title":"Hepatology"},{"issue":"4","key":"613_CR87","doi-asserted-by":"publisher","first-page":"e0175717","DOI":"10.1371\/journal.pone.0175717","volume":"12","author":"S McPherson","year":"2017","unstructured":"McPherson S, Wilkinson N, Tiniakos D, Wilkinson J, Burt AD, McColl E, et al. A randomised controlled trial of losartan as an anti-fibrotic agent in non-alcoholic steatohepatitis. PLoS One. 2017;12(4):e0175717. https:\/\/doi.org\/10.1371\/journal.pone.0175717.","journal-title":"PLoS One."},{"issue":"9","key":"613_CR88","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1002\/ejhf.1853","volume":"22","author":"K Suzuki","year":"2020","unstructured":"Suzuki K, Claggett B, Minamisawa M, Packer M, Zile MR, Rouleau J, et al. Liver function and prognosis, and influence of sacubitril\/valsartan in patients with heart failure with reduced ejection fraction. Eur J Heart Fail. 2020;22(9):1662\u201371. https:\/\/doi.org\/10.1002\/ejhf.1853.","journal-title":"Eur J Heart Fail"}],"container-title":["Current Heart Failure Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11897-023-00613-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11897-023-00613-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11897-023-00613-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T08:30:04Z","timestamp":1694766604000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11897-023-00613-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,4]]},"references-count":88,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["613"],"URL":"https:\/\/doi.org\/10.1007\/s11897-023-00613-1","relation":{},"ISSN":["1546-9530","1546-9549"],"issn-type":[{"value":"1546-9530","type":"print"},{"value":"1546-9549","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,4]]},"assertion":[{"value":"14 June 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights"}}]}}